{"id":"tp-44904","type":"article-newspaper","title":"Bernstein Moves Alnylam to Market Perform Over Nucresiran Trial Concerns","author":"Enna Lee","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/investing/44904","datePublished":"2026-10-30T16:42:38.000Z","dateModified":"2026-10-30T16:42:38.000Z","language":"en","abstract":"The change concerns TRITON-CM, a Phase 3 trial of nucresiran, Alnylam's next-generation RNAi therapeutic.","section":"Investing","references":[]}